ZVRA

In the past six months, ZVRA's stock has trended upwards by 24.86%. A significant event impacting the stock price was the company's strong first-quarter 2026 financial results, reported on May 6, 2026. Zevra Therapeutics reported a net income of $37.9 million, or $0.60 per diluted share, surpassing analyst expectations. Net revenue surged to $36.2 million, a 78% increase year-over-year, driven by robust sales of MIPLYFFA and contributions from other revenue streams. The strategic divestiture of the SDX portfolio for $50.0 million, which generated $40.5 million in net proceeds in Q1 2026, enabled the company to fully prepay its $63.1 million term loan, achieving a debt-free status with $236.8 million in cash, cash equivalents, and securities as of March 31, 2026. Following the earnings announcement, Zevra's stock price increased by 6.03% in aftermarket trading.